The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2012;(4): 43‑46

Read: 383 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2012;(4):43‑46. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390.
  2. Chen J., Radford M.J., Wang Y., et al. Are Β-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med 2000;160:947-952.
  3. Kramer J.M,. Hammill B., Anstrom K.J., et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 2006;152:454, e1-e8.
  4. Bhatt D.L., Steg P.G., Ohman E.M., et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189.
  5. Ohman E.M., Bhatt D.L., Steg P.G., et al; REACH Registry Investigators. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151:786, e1-e10.
  6. Steg P.G., Bhatt D.L., Wilson P.W., et al; REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206.
  7. Bhatt D.L., Eagle K.A., Ohman E.M., et al; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-1357.
  8. Snow P.J. Effect of propranolol in myocardial infarction. Lancet 1965;2:551-553.
  9. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
  10. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
  11. Freemantle N., Cleland J., Young P., et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-1737.
  12. Bangalore S., Messerli F.H., Cohen J.D., et al; INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an International Verapamil SR-Trandolapril (INVEST) substudy. Am Heart J 2008;156:241-247.
  13. Smith S.C. Jr, Benjamin E.J., Bonow R.O., et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458-2473.
  14. Hamm C.W., Bassand J.P., Agewall S., et al; ESC Committee for Practice Guidelines; Document Reviewers. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
  15. Jonsson G., Abdelnoor M., Müller C., et al. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction: a single-centre, randomized study of 232 patients. Cardiology 2005;103:148-155.
  16. Modern Medicine website. Top 200 generic drugs by total prescriptions. Available at: www.drugtopics .modernmedicine.com/drugtopics/data/articlestandard //drugtopics/252011/727243/article.pdf. Accessed March 23, 2012.
  17. Fox K., Garcia M.A., Ardissino D., et al; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-1381.
  18. Bangalore S., Kamalakkannan G., Messerli F.H. Beta-blockers: no longer an option for uncomplicated hypertension. Curr Cardiol Rep 2007;9:441-446.
  19. Bangalore S., Messerli F.H. Beta-blockers and exercise. J Am Coll Cardiol 2006;48:1284-1285.
  20. Bangalore S., Messerli F.H. Hypertension in the elderly: a compelling contraindication for beta-blockers? J Hum Hypertens 2007;21:259-260.
  21. Bangalore S., Messerli F.H. Beta-blockers as fourth-line therapy for hypertension: stay the course. Int J Clin Pract 2008;62:1643-1646.
  22. Bangalore S., Messerli F.H., Kostis J.B., Pepine C.J. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007;50:563-572.
  23. Bangalore S., Parkar S., Grossman E., Messerli F.H. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-1262.
  24. Bangalore S., Parkar S., Messerli F.H. How useful are beta-blockers in cardiovascular disease? Anadolu Kardiyol Derg. 2006;6:358-363.
  25. Bangalore S., Sawhney S., Messerli F.H. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482-1489.
  26. Bangalore S., Wild D., Parkar S., et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008;52:1062-1072.
  27. Messerli F.H., Bangalore S. Resting heart rate and cardiovascular disease: the beta-blockerhypertension paradox. J Am Coll Cardiol 2008;51:330-331.
  28. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? a meta-analysis. Lancet 2005;366:1545-1553.
  29. Wiysonge C.S., Bradley H., Mayosi B.M., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003.
  30. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease, part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
  31. Nice website. The clinical management of primary hypertension in adults. http://www.nice.org.uk /guidance/index.jsp?action=download&o=53228. Accessed December 3, 2011.
  32. National Collaborating Centre for Chronic Conditions. Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update. London, England: Royal College of Physicians;2006.
  33. Chen Z.M., Pan H.C., Chen Y.P., et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-1632.
  34. Meine T.J., Roe M.T., Chen A.Y., et al; CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J 2005;149:1043-1049.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.